ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,143,308 | -0.7% | 742,200 | +12.4% | 0.03% | -6.5% |
| Q2 2023 | $20,294,548 | +19.2% | 660,200 | +39.7% | 0.03% | +14.8% |
| Q1 2023 | $17,024,175 | +9357.1% | 472,500 | +10273.2% | 0.03% | – |
| Q4 2022 | $180,014 | -96.8% | 4,555 | -96.7% | 0.00% | -100.0% |
| Q3 2022 | $5,611,000 | +22.8% | 139,655 | +28.5% | 0.01% | +25.0% |
| Q2 2022 | $4,568,000 | +3.5% | 108,655 | -4.1% | 0.01% | +33.3% |
| Q1 2022 | $4,412,000 | +8.1% | 113,255 | +10.6% | 0.01% | +50.0% |
| Q4 2021 | $4,081,000 | -15.8% | 102,411 | -23.7% | 0.00% | -20.0% |
| Q3 2021 | $4,849,000 | +11726.8% | 134,170 | +13384.4% | 0.01% | – |
| Q2 2021 | $41,000 | -99.4% | 995 | -99.3% | 0.00% | -100.0% |
| Q1 2021 | $6,648,000 | +22.7% | 152,400 | +40.7% | 0.01% | +12.5% |
| Q4 2020 | $5,420,000 | +19.0% | 108,300 | 0.0% | 0.01% | -11.1% |
| Q3 2020 | $4,556,000 | – | 108,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |